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Abstract
Introduction The objective of this study was to clarify the
efficacy and mechanism of action of direct hemoperfusion with
an immobilized polymyxin B fiber column (DHP-PMX) in patients
with acute lung injury or acute respiratory distress syndrome
caused by sepsis.
Method Thirty-six patients with sepsis were included. In each
patient a thermodilution catheter was inserted, and the oxygen
delivery index and oxygen consumption index were measured.
DHP-PMX was performed in patients with a normal oxygen
delivery index and oxygen consumption index (> 500 ml/minute
per m2 and >120 ml/minute per m2, respectively). The Acute
Physiology and Chronic Health Evaluation II score was used as
an index of the severity of sepsis, and survival was assessed
after 1 month. The humoral mediators measured were the
chemokine IL-8, plasminogen activator inhibitor-1, and
neutrophil elastase (NE). These mediators were measured
before DHP-PMX treatment, and at 24, 48, and 78 hours after
the start of treatment. The arterial oxygen tension (PaO2)/
fractional inspired oxygen (FiO2) ratio was measured before
DHP-PMX treatment and at 24, 48, 72, 92, and 120 hours after
the start of treatment.
Results All patients remained alive after 1 month. Before DHP-
PMX treatment, the Acute Physiology and Chronic Health
Evaluation II score was 24 ± 2.0, the IL-8 level was 54 ± 15.8
pg/ml, plasminogen activator inhibitor-1 was 133 ± 28.1 ng/ml,
and NE was 418 ± 72.1 µg/l. These three humoral mediators
began to decrease from 24 hours after DHP-PMX treatment,
and the decline became significant from 48 hours onward. The
PaO2/FiO2 ratio was 244 ± 26.3 before DHP-PMX treatment
but improved significantly from 96 hours onward. There were
significant negative correlations between the PaO2/FiO2 ratio
and blood levels of NE and IL-8.
Conclusion The mechanism of action of DHP-PMX is still not
fully understood, but we report the following findings. The mean
blood levels of plasminogen activator inhibitor-1, NE, and IL-8
were significantly decreased from 48 hours after DHP-PMX
treatment. The mean PaO2/FiO2 ratio was significantly improved
from 96 hours after DHP-PMX treatment. Improvement in the
PaO2/FiO2 ratio appeared to be related to the decreases in
blood NE and IL-8 levels.
Introduction
Since the American College of Chest Physicians and the Soci-
ety of Critical Care Medicine proposed broad definitions of the
terms 'sepsis' and the 'systemic inflammatory response syn-
drome' (SIRS) in 1992 [1], the concept of sepsis has changed
dramatically. However, despite recent progress in new thera-
pies, sepsis and septic shock are still major causes of multiple
organ failure (MOF), and clinical outcomes remain unsatisfac-
tory for patients with MOF [2]. Many clinicians have made
great efforts to improve the prognosis of sepsis and SIRS.
ALI = acute lung injury; APACHE = Acute Physiology and Chronic Health Evaluation; ARDS = acute respiratory distress syndrome; DHP-PMX = 
direct hemoperfusion with an immobilized polymyxin B fiber column; FiO2 = fractional inspired oxygen; IL = interleukin; MOF = multiple organ failure; 
NE = neutrophil elastase; PAI = plasminogen activator inhibitor; PaO2 = arterial oxygen tension; PEEP = positive end-expiratory pressure; SIRS = 
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Despite this, clinical trials of anti-endotoxin monoclonal anti-
bodies [3,4] and cytokine antagonists have proved unsuc-
cessful in controlling either sepsis or SIRS [5].
In sepsis and SIRS a cascade of inflammatory responses
leads to the production of proinflammatory cytokines, which
are released from macrophages and monocytes after stimula-
tion by lipopolysaccharide produced by Gram-negative bacte-
ria or lipoteichoic acids produced by Gram-positive bacteria.
These cytokines are importantly involved in the progression
from sepsis to MOF. To inhibit this cascade of ongoing inflam-
matory reactions, a new therapy that eliminates the pathogenic
toxins that trigger these reactions has been developed in
Japan. A polymyxin B immobilized fiber column (PMX; Toray
Industries Inc., Tokyo, Japan) was released in Japan in 1994
and it has been used for the treatment of endotoxemia. PMX
therapy not only inhibits lipopolysaccharide production by
Gram-negative bacteria but also lipoteichoic acid production
by Gram-positive bacteria, as demonstrated in an experimental
study [6]. It was reported in an experimental study [7] that
removal of endotoxin with PMX can significantly improve sur-
vival rate, and the indications for PMX have gradually been
defined.
However, Vincent and coworkers [8] found no difference in
survival when they investigated the clinical benefit of direct
hemoperfusion with PMX (DHP-PMX) in a randomized control-
led study. On the other hand, in their randomized controlled
study, Tani and colleagues [9] reported improved survival in
patients with Acute Physiology and Chronic Health Evaluation
(APACHE) II scores in the range 20–30. In an uncontrolled
observational study [10] and a case report [11] DHP-PMX
was used to treat peritonitis caused by colorectal perforation
and acute cholecystitis, respectively, and PMX has proved to
be of clinical benefit in these conditions. In their controlled
observational study, Tsushima and coworkers [12] reported
that PMX was able to improve significantly the arterial oxygen
tension (PaO2)/fractional inspired oxygen (FiO2) ratio in
patients with acute lung injury (ALI) or acute respiratory dis-
tress syndrome (ARDS) [13], although the mechanism of
action was unclear. The incidence of ALI and ARDS is
increased, and levels of blood humoral mediators are higher in
patients with sepsis than in patients with trauma [14,15]. Thus,
in addition to improving hemodynamics, improvement in pul-
monary oxygenation in patients with ALI or ARDS has become
an important goal during treatment for sepsis.
The following mechanisms have been suggested to explain the
development of ALI and ARDS in patients with sepsis. Bacte-
rial products such as endotoxin induce production of IL-8 by
vascular endothelial cells and IL-8 activates neutrophils. As a
result, the expression of adhesion molecules such as CD11/
CD18 by activated neutrophils increases, as does the produc-
tion of E-selectin and intercellular adhesion molecule-1 by pul-
monary vascular endothelial cells. Neutrophils adhere to the
pulmonary vascular endothelium by binding to these adhesion
molecules, pass through the junctions between endothelial
cells, and migrate into the extravascular space. Neutrophils
cause damage to the pulmonary vascular endothelium by
releasing oxygen radicals, proteinases, leukotrienes, and other
proinflammatory molecules such as platelet-activating factor,
thus impairing the barrier function of the pulmonary capillaries
and leading to the onset of ALI or ARDS [16,17].
Based on the above mechanisms of development for ALI and
ARDS, we formulated a hypothesis that the inhibitory effect of
PMX on activation of chemokines, neutrophils, and vascular
endothelial cells was associated with improvement in the
PaO2/FiO2 ratio. In the present study we measured peripheral
blood levels of IL-8, neutrophil elastase (NE), and plasminogen
activator inhibitor (PAI)-1 (a marker of vascular endothelial cell
activation) [18] over time to examine whether PMX could
inhibit the production of these humoral mediators and improve
the PaO2/FiO2 ratio.
Materials and methods
Selection of patients
This study was approved by the hospital ethics committee,
and proper informed consent (oral or written) was obtained
from each patient or their family. Patients with a clinical diag-
nosis of sepsis according to the criteria proposed by the
American College of Chest Physicians/Society of Critical
Care Medicine Consensus Conference were enrolled in the
study [1]. Before the start of PMX treatment, global oxygen
metabolism was measured. A thermodilution catheter
(Edwards Life Sciences LLC, Irvine, CA, USA) was used to
determine the oxygen delivery index and oxygen consumption
index as parameters of oxygen metabolism. A thermodilution
catheter was also used to monitor hemodynamics, and fluid
balance was managed to maintain the central venous pressure
in the range 7–10 mmHg. Criteria for inclusion in the study
were the following findings within the previous 24 hours: signs
of SIRS caused by infection (including fever or hypothermia
[temperature > 38°C or < 36°C, respectively], tachycardia [>
90 beats/minute], tachypnea [> 20 breaths/minute], or an
arterial carbon dioxide tension < 32 mmHg or mechanical ven-
tilation, and a white blood cell count > 12.0 × 104/l or < 4.0 ×
104/l or at least 10% immature neutrophils); mean arterial
pressure > 60 mmHg irrespective of the use of catecho-
lamines; stable global oxygen metabolism (oxygen delivery
index > 500 ml/minute per m2 and oxygen consumption index
> 120 ml/minute per m2); and a diagnosis of ALI or ARDS
according to the criteria established by the American-Euro-
pean Consensus Conference [13].
The diagnostic criteria for ALI and ARDS of the American-
European Consensus Conference are as follows: acute onset
of lung injury, diffuse bilateral infiltrates on chest X-ray film, a
PaO2/FiO2 ratio < 200 mmHg for ARDS and < 300 mmHg for
ALI, and a pulmonary artery occlusion pressure < 19 mmHg orAvailable online http://ccforum.com/content/9/6/R653
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no clinical evidence of congestive heart failure. Exclusion cri-
teria were age < 18 years, mean arterial pressure ≤ 60 mmHg
irrespective of the use of catecholamines, and impaired global
oxygen metabolism.
The APACHE II score [19] was employed to assess of the
severity of each patient's condition before DHP-PMX was per-
formed. Survival of the patients was assessed at 1 month after
treatment.
The three humoral mediators measured were IL-8 as a chem-
okine, PAI-1 as an index of vascular endothelial cell activation,
and NE as an index of neutrophil activation. These mediators
were measured before DHP-PMX treatment, and at 24, 48,
and 72 hours after the start of therapy. Blood samples for the
measurement of these mediators were collected from a
peripheral vein. The neutrophil count was also determined. The
PaO2/FiO2 ratio was used as an index of pulmonary oxygena-
tion, and was measured before institution of DHP-PMX, and at
24, 48, 72, 92, and 120 hours after the start of treatment.
DHP-PMX was performed in 36 patients who had sepsis
caused by Gram-positive or Gram-negative bacteria, and who
fulfilled the inclusion criteria given above.
Ventilation
Because they had ALI or ARDS, all of the patients included in
the study needed mechanical ventilation; the tidal volume and
plateau pressure were set at 6 ml/kg [20] and ≤ 30 cmH2O,
respectively. The initial ventilation mode was volume-targeted
assist control, which was changed to pressure-targeted assist
control if the plateau pressure increased. The positive end-
expiratory pressure (PEEP) was set at 5–15 cmH2O and the
ventilation rate at 10–35 breaths/minute.
The ventilator protocol at our hospital involved FiO2 initially
being set at 1.0 and PEEP at 10 cmH2O. Then PEEP was
increased in 2 cmH2O increments up to 15 cmH2O if PaO2
remained below 55 mmHg on arterial blood gas analysis.
When PaO2 was 80 mmHg or greater, FiO2 was decreased by
0.1. If PaO2 was 100 mmHg or greater, even after decreasing
FiO2 to 0.6, then PEEP was decreased by 2 cmH2O. PEEP
was discontinued at a PaO2/FiO2 ratio of 300 or greater, and
PEEP under 5 cmH2O was not used.
Both ventilation and weaning from the ventilator were per-
formed according to standardized protocols.
Direct hemoperfusion
DHP-PMX was performed using a column of polystyrene fibers
to which polymyxin B was covalently bound at a weight ratio of
0.5%. Binding of polymyxin B to the fibers was confirmed to
be strong [7]. Blood access for DHP-PMX was obtained via a
double-lumen catheter inserted into the femoral vein using
Seldinger's method. Treatment was carried out for 3 hours at
a flow rate of 80–100 ml/minute, and DHP-PMX was per-
formed twice within 24 hours. Nafamostat mesilate (Torii Co.,
Ltd, Tokyo, Japan) was used as the anticoagulant. This is a ser-
ine protease inhibitor that exerts its anticoagulant effect prima-
rily by inhibiting thrombin. The half-life of nafamostat mesilate
is 8 minutes, and so its anticoagulant effect was confined to
the extracorporeal circuit.
Plasminogen activator inhibitor-1 assay
PAI-1 was measured in duplicate by an enzyme-linked immu-
nosorbent assay (Fuji Revio Inc., Tokyo, Japan). PAI-1 is known
to have various forms in blood, including an active form, an
inactive form, a latent form, tissue plasminogen activator/PAI-
1 complex, and vitronectin/PAI-1 complex. We measured total
PAI-1 in the present study to determine the total amount of
PAI-1 produced by vascular endothelial cells.
Measurement of neutrophil elastase
The blood level of NE was measured by using a commercial
enzyme immunoassay kit (Sanwa Chemical Institute, Nagoya,
Japan). Two forms of NE (free NE and NE/α1-antitrypsin com-
plex) can be detected using the kit. The normal NE level, deter-
mined in 139 healthy persons using this kit, was found to be
29 ± 2.7 µg/l (SRL Inc., Tokyo Japan, unpublished data).
Measurement of IL-8
Four blood samples were collected from a peripheral vein.
After centrifugation, serum was stored for a maximum of one
month at -70°C. Then the serum level of IL-8 was determined
using a commercially available specific enzyme-linked immu-
nosorbent assay kit for IL-8 (Ohtsuka Pharma Co., Tokyo,
Japan), in accordance with the manufacturer's instructions.
Table 1
Demographic characteristics and underlying diseases of the 36 
patients
Characteristic Value
Patients (n)3 6
Age (years) 62 ± 18.5 (range 28–85)
Sex (male/female; n)2 1 / 1 5
Underlying disease (n)
Respiratory disease 11
Neurological disease 9
Cardiovascular disease 6
Diabetes mellitus 4
Recent trauma 5
Chronic liver disease 1Critical Care    Vol 9 No 6    Kushi et al.
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Statistical analysis
Results are expressed as mean ± standard error. The unpaired
Wilcoxon's test or one-way analysis of variance was used to
determine statistically significant differences. P < 0.05 was
considered statistically significant. The correlation coefficient
was obtained using Spearman's equation.
Results
DHP-PMX was performed 72 times in 36 patients (21 men
and 15 women), aged 28–85 years old (mean 62 ± 18.5
years). Treatment was performed twice (for 3 hours/session)
within a 24-hour period. As shown in Table 1, the patients had
various underlying diseases and had multiple conditions. Table
2 shows the sources of infection; pneumonia was the most fre-
quent type of primary infection. Table 3 shows the causative
organisms. The most commonly isolated microorganisms were
Gram-negative bacteria, and 48 bacterial strains were
detected in the 36 patients. Antibiotic therapy was judged to
be adequate when the patient received drugs to which each
isolated microorganism was sensitive. Although it was not
possible to identify bacteria in two patients, cultures were pos-
itive in 34 patients and adequate antibiotic treatment was
given to them.
The APACHE II score was 24 ± 2.0 before DHP-PMX. (Pro-
pofol was used as a sedative, and it was temporarily discontin-
ued from 06:00 to 08:00 hours and the Glasgow Coma Scale
score was evaluated thereafter.) The mean PaO2/FiO2 ratio
was 244 ± 26.3 and the mean level of PEEP was 8 ± 1.3
cmH2O at the start of DHP-PMX treatment. Because PEEP
was discontinued at a PaO2/FiO2 ratio of 300 or above, its
mean duration was approximately 81 ± 13.5 hours.
The PAI-1 level was 133 ± 28.1 ng/ml before DHP-PMX treat-
ment, whereas it was 67 ± 17.4 ng/ml at 24 hours after the
start of treatment, 54 ± 13.6 ng/ml at 48 hours, and 52 ± 9.8
ng/ml at 72 hours, with decreases being statistically signifi-
cant from 48 hours onward compared with baseline (P < 0.05;
Fig. 1).
The NE level was 418 ± 72.1 µg/l before DHP-PMX treatment,
whereas it was 366 ± 74.0 µg/l at 24 hours after the start of
treatment, 274 ± 42.5 µg/l at 48 hours, and 249 ± 41.3 µg/l
at 72 hours, with decreases being statistically significant from
48 hours onward compared with baseline (P < 0.05; Fig. 2).
Table 2
Locations of infection
Location n
Respiratory system 12
Abdominal cavity 6
Central nervous system 6
Urinary tract 4
Biliary tract 3
Cardiovascular system 3
Others 2
Table 3
Causative organisms
Organisms n
Gram-negative bacteria
Pseudomonas aeruginosa 11
Escherichia coli 8
Klebsiella pneumoniae 6
Neisseria spp. 3
Vibrio and Citrobactor spp. 1
Gram-positive bacteria
Staphylococcus aureus 7
α-Streptococcus 4
Staphylococcus epidermidis 3
Corynebacterium spp. 1
Enterococcus faecalis 1
Fungi
Candida albicans 3
Figure 1
Changes in PAI-1 Changes in PAI-1. The plasminogen activator inhibitor (PAI)-1 level was 
1,138 ± 26.3 ng/ml before direct hemoperfusion with an immobilized 
polymyxin B fiber column (DHP-PMX), but it was 67 ± 17.4 ng/ml at 24 
hours after the start of treatment, 54 ± 13.6 ng/ml at 48 hours, and 52 
± 9.8 ng/ml at 72 hours, with statistically significant decreases from 48 
hours onward compared with baseline (P < 0.05).Available online http://ccforum.com/content/9/6/R653
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The mean neutrophil count was 14.157 ± 2.1785 × 109/l
before DHP-PMX treatment, but it was 13.054 ± 1.816 × 109/
l at 24 hours after the start of treatment, 13.343 ± 1.3978 ×
109/l at 48 hours, and 12.206 ± 1.753 × 109/l at 72 hours;
differences from baseline were not statistically significant.
The IL-8 level was 54 ± 15.8 pg/ml before DHP-PMX treat-
ment, but it was 27 ± 7.5 pg/ml at 24 hours after the start of
treatment, 19 ± 4.3 pg/ml at 48 hours, and 20 ± 4.5 pg/ml at
72 hours, with statistically significant decreases compared
with baseline from 48 hours onward (P < 0.05; Fig. 3).
The PaO2/FiO2 ratio was 244 ± 26.3 before DHP-PMX treat-
ment. It increased to 274 ± 28.6 at 24 hours afterward the
start of treatment, 289 ± 26.2 at 48 hours, 348 ± 46.0 at 72
hours, 322 ± 22.1 at 96 hours, and 352 ± 25.4 at 120 hours,
with significant improvements compared with baseline from
96 hours onward (P < 0.05; Fig. 4).
The correlation coefficients (r values) for the relationships
between the PaO2/FiO2  ratio and each of the humoral
mediators were as follows: -0.186 (P = 0.216) between the
log-transformed PaO2/FiO2 ratio and log-transformed PAI-1
value; -0.337 (P  = 0.0198) between the log-transformed
PaO2/FiO2 ratio and log-transformed NE value; and -0.417 (P
= 0.0032) between the log-transformed PaO2/FiO2 ratio and
log-transformed IL-8 value. Thus, there were statistically signif-
icant inverse relationships between the PaO2/FiO2 ratio and
peripheral blood levels of NE and IL-8 (Figs 5 and 6).
Discussion
Patient selection
No standard criteria for the use of DHP-PMX have been estab-
lished. It has been variously reported that an IL-6 level of 1,000
pg/ml or greater [21], an APACHE II score of 25 or greater
[22], an APACHE II score of 30 or greater [9], and a cardiac
Figure 2
Changes in NE Changes in NE. The neutrophil elastase (NE) level was 443 ± 68.2 µg/
l before direct hemoperfusion with an immobilized polymyxin B fiber col-
umn (DHP-PMX), but it was 366 ± 74.0 µg/l at 24 hours after the start 
of treatment, 274 ± 42.5 µg/l at 48 hours, and 249 ± 41.3 µg/l at 72 
hours, with statistically significant decreases from 48 hours onward 
compared with baseline (P < 0.05).
Figure 3
Changes in IL-8 Changes in IL-8. The IL-8 level was 54 ± 14.6 pg/ml before direct 
hemoperfusion with an immobilized polymyxin B fiber column (DHP-
PMX), but it was 27 ± 7.5 pg/ml at 24 hours after the start of treatment, 
19 ± 4.3 pg/ml at 48 hours after, and 20 ± 4.5 pg/ml at 72 hours after, 
with a statistically significant decrease from 48 hours onward com-
pared with baseline (P < 0.05).
Figure 4
Changes in PaO2/FiO2 ratio Changes in PaO2/FiO2 ratio. The arterial oxygen tension (PaO2)/frac-
tional inspired oxygen (FiO2) ratio was 244 ± 26.3 before direct hemo-
perfusion with an immobilized polymyxin B fiber column (DHP-PMX). It 
increased to 274 ± 28.6 at 24 hours after the start of treatment, 289 ± 
26.2 at 48 hours, 348 ± 46.0 at 72 hours, 322 ± 22.1 at 96 hours, and 
352 ± 25.4 at 120 hours, with statistically significant improvement from 
96 hours onward compared with baseline (P < 0.05).Critical Care    Vol 9 No 6    Kushi et al.
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index of 6 l/minute per m2 or greater [23] are indicators of poor
prognosis at the start of DHP-PMX treatment. The reported
efficacy of DHP-PMX also varies among medical institutions,
depending on the time of starting treatment. In the present
study, DHP-PMX was performed before the deterioration of
organ perfusion and global oxygen metabolism. Our use of cri-
teria targeting global oxygen metabolism and the mean blood
pressure was based on the concept that DHP-PMX should be
started before the tissues and cells have been significantly
affected, even if some organ disfunction is present. Once
shock occurs and organ ischemia progresses, cellular disfunc-
tion at the molecular level becomes severe, and this makes it
difficult to assess the effect of DHP-PMX. Therefore, we
selected patients for this therapy according to criteria that
excluded those already in shock. It is perhaps a result of the
early introduction of DHP-PMX before oxygen metabolism had
deteriorated that all of the patients remained alive after 1
month.
Plasminogen activator inhibitor-1
PAI-1 is a protein with a molecular weight of 50 kDa that is pro-
duced by vascular endothelial cells and plays a central role in
the activation of fibrinolysis [24]. It has recently attracted
attention as a marker of vascular endothelial cell activation
[18]. We measured total PAI-1 in the present study to
determine the total production of this mediator by vascular
endothelial cells.
Proinflammatory cytokines such as TNF-α and IL-1β stimulate
vascular endothelial cells, induce the expression of adhesion
molecules, and cause activated neutrophils to stimulate PAI-1
production by vascular endothelial cells, thus inhibiting fibri-
nolysis [18]. In the present study, PAI-1 was significantly lower
at 48 and 72 hours after the start of DHP-PMX then the base-
line value. Rather than DHP-PMX directly inhibitiing PAI-1 pro-
duction, it seems more likely that adsorption of pathogenic
bacteria prevented the release of inflammatory cytokines and
reduced the stimulation of vascular endothelial cells to lower
the PAI-1 level indirectly.
Neutrophil elastase
NE is a glycoprotein with a molecular weight of approximately
30 kDa and it has three isozymes. Its physiologic actions are
proteolysis of bacteria and foreign materials. Because of low
substrate specificity, however, NE can also attack various host
proteins such as plasma proteins, coagulation factors, com-
plement, elastin, and collagen [25]. Intact cells can also be
damaged by this protease [26]. Neutrophils are believed to be
an important precipitating factor in the pathogenesis of ARDS
[16,17]. Indeed, neutrophils may contribute to the develop-
ment of lung disfunction by releasing oxygen radicals and
proteolytic enzymes that induce the parenchymal cell damage
and connective tissue destruction characteristic of ARDS
[16,17].
We investigated changes in circulating NE following DHP-
PMX and found that blood levels after 48 and 72 hours were
significantly lower than before treatment. Adsorption of patho-
genic toxins may have prevented the release of inflammatory
cytokines [22], resulting in less stimulation of neutrophils,
rather than DHP-PMX directly preventing cytokine production
or neutrophils being cleared from the blood by the column,
because the neutrophil count was not altered by this
treatment. Thus, DHP-PMX appears to prevent the activation
of neutrophils, albeit indirectly. The ability of DHP-PMX to
Figure 5
Relationship between the PaO2/FiO2 ratio and NE Relationship between the PaO2/FiO2 ratio and NE. There was an 
inverse relationship between the arterial oxygen tension (PaO2)/frac-
tional inspired oxygen (FiO2) ratio (P/F ratio) and peripheral blood neu-
trophil elastase (NE) level. The correlation coefficient between the log-
transformed PaO2/FiO2 ratio and log-transformed NE value was -0.337 
(P = 0.0198).
Figure 6
Relationship between the PaO2/FiO2 ratio and IL-8 Relationship between the PaO2/FiO2 ratio and IL-8. There was an 
inverse relationship between the arterial oxygen tension (PaO2)/frac-
tional inspired oxygen (FiO2) ratio (P/F ratio) and peripheral blood IL-8 
level. The correlation coefficient between the log-transformed PaO2/
FiO2 ratio and log-transformed IL-8 value was -0.417 (P = 0.0032).Available online http://ccforum.com/content/9/6/R653
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prevent activation of vascular endothelial cells [27] and reduce
the blood level of NE might help to decrease organ disfunc-
tion, and the same mechanisms are considered to be
associated with improvement in PaO2/FiO2  ratio in the
patients with ALI and ARDS studied here.
Interleukin-8
IL-8 is a 6.5 kDa cytokine [28] that belongs to a supergene
family of host defense molecules characterized by potent neu-
trophil activation in vitro [29]. It can be produced by several
types of cells in vitro, including macrophages, lymphocytes,
neutrophils, fibroblasts, and endothelial cells, in response to a
variety of stimuli such as endotoxin, viruses, and other
cytokines such as IL-1 or tumor necrosis factor [29]. Similar to
PAI-1 and NE, the mean blood level of IL-8 was significantly
decreased from 48 hours after DHP-PMX compared with the
baseline value. This observation suggests that removal of path-
ogenic toxins from the blood indirectly inhibited the release of
IL-8 from IL-8 producing cells, as was observed for PAI-1 and
NE. In fact, an in vitro study [30] has demonstrated that
absorption of inflammatory cytokines by PMX is quite limited.
However, there has been no previous report on the effect of
this treatment on IL-8. The results of the present study suggest
that the inhibitory effect of DHP-PMX on IL-8, which is a key
mediator of inflammatory reactions [31], may contribute to
improvement in PaO2/FiO2 ratio.
Ventilation parameters may be another factor that influences
circulating IL-8 concentration. Parsons and coworkers [32]
reported that mechanical ventilation with a lower tidal volume
of 6 ml/kg reduced the mean blood IL-8 level by approximately
12% in patients with ALI on the third day after the onset, sug-
gesting that the decrease of blood IL-8 levels observed in our
study was possibly associated with mechanical ventilation at
low tidal volumes. However, the mean blood IL-8 level was
decreased by approximately 72% compared with baseline on
day 3 after the onset of treatment, which may represent a syn-
ergistic effect between mechanical ventilation at low tidal vol-
umes and DHP-PMX.
Relationship between the PaO2/FiO2 ratio and humoral 
mediators
During ventilation, PEEP and fluid balance are factors that are
likely to influence pulmonary oxygenation, other than humoral
mediators. The mean PaO2/FiO2 ratio was 244 ± 26.3 and the
mean level of PEEP was 8 ± 1.3 cmH2O at the start of DHP-
PMX. Because PEEP was discontinued at a PaO2/FiO2 ratio
of 300 or greater, its mean duration was approximately 81 ±
13.5 hours. The level of PEEP was gradually reduced during
this period, and PEEP of 5 cmH2O or less was not employed.
Given that the PaO2/FiO2 ratio improved while PEEP was
gradually reduced, it is not likely that PEEP directly contributed
to the improvement in pulmonary oxygenation. A thermodilu-
tion catheter was inserted before the start of treatment to mon-
itor oxygen metabolism and hemodynamics for 7 days.
Because the central venous pressure was maintained
between 7 and 10 mmHg in all patients, it is not likely that the
fluid balance had a direct influence on differences in pulmo-
nary oxygenation.
Tsushima and coworkers [12] reported that the PaO2/FiO2
ratio was significantly improved at 2 hours after DHP-PMX in
all 20 patients with ALI or ARDS that they treated. They sug-
gested that the observed improvement in PaO2/FiO2 ratio was
related to inhibition of the production of inflammatory media-
tors and consequent suppression of systemic inflammation,
both of which are caused by modulation of activated
mononuclear cells and neutrophils by PMX, although the
detailed mechanism of action remains unknown.
In the present study, although the PaO2/FiO2 ratio was signif-
icantly improved from 96 hours after DHP-PMX, no improve-
ment was observed soon after treatment (24 hours). The
patients included had definite ALI and/or ARDS and did not
have cardiogenic pulmonary edema, according to assessment
with a thermodilution catheter before DHP-PMX. The following
mechanisms underlying the development of ALI and ARDS in
patients with sepsis have been suggested. Bacterial sub-
stances such as endotoxin induce the production of IL-8 by
stimulating pulmonary vascular endothelial cells and thus acti-
vate neutrophils. Production of adhesion molecules is then
accelerated, causing neutrophils to adhere to pulmonary vas-
cular endothelial cells and migrate into the extravascular
space. Neutrophils accumulate locally in the lungs along the
concentration gradients of chemotactic factors such as IL-8.
Neutrophils then cause damage to pulmonary vascular
endothelial cells and impair the barrier function of pulmonary
capillaries, leading to the development of ALI or ARDS
[16,17]. Considering the above mechanisms, it is unlikely that
PaO2/FiO2 ratio would improve immediately after DHP-PMX.
In the present study we examined correlations between the
PaO2/FiO2 ratio and circulating levels of mediators that are
considered to be associated with the development of ARDS
(i.e. PAI-1, NE, and IL-8). Our findings indicate that there are
significant negative correlations between the PaO2/FiO2 ratio
and IL-8 and NE levels. Jorens and coworkers [33] reported a
negative correlation between the PaO2/FiO2 ratio and the IL-8
level in bronchoalveolar lavage fluid as well as between the
PaO2/FiO2 ratio and infiltration of neutrophils in patients with
ARDS. Although the correlations demonstrated in the present
study did not indicate such strong relationships, perhaps
because we measured peripheral blood levels, the results of
our study are consistent with the findings of Jorens and
coworkers.
We used PAI-1 as an index of vascular endothelial cell activa-
tion, but no significant relationship with the PaO2/FiO2 ratio
was identified, probably resulting from testing of peripheral
blood samples. If we had measured the PAI-1 level inCritical Care    Vol 9 No 6    Kushi et al.
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bronchoalveolar lavage fluid, then a significant correlation with
the PaO2/FiO2 ratio might have been demonstrated. The rea-
sons why a period of 96 hours is required to detect improve-
ment in the PaO2/FiO2 ratio is that the patients had definite
ARDS or ALI, and that 48 hours after DHP-PMX were required
for decreases in PAI-1, NE, and IL-8 concentrations to occur.
Because this work is an uncontrolled observational study,
observed changes can not be concluded to result from extra-
corporeal treatment. It will be necessary to conduct controlled
studies in this area in the future.
Conclusion
The mechanism of action of DHP-PMX is not fully understood,
but DHP-PMX significantly decreased blood levels of PAI-1,
NE and IL-8, and significantly improved the PaO2/FiO2 ratio.
There were significant negative correlations between the
PaO2/FiO2 ratio and IL-8 and NE levels. The present study
showed that early performance of DHP-PMX eliminated
humoral mediators and improved pulmonary oxygenation.
This was a prospective uncontrolled observational study
including a limited number of patients. The results of larger,
better powered, multicenter clinical trials are necessary if we
are to assess accurately the benefit of DHP-PMX.
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